drugset / Trial / NCT03864250
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This random, open, control and multicenter clinical trial mainly aims to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN).
Timeline
- Start
- 2018-11-26
- Primary completion
- 2020-11
- Completion
- 2021-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Prednisone | Other / unclassified | 0.5 mg/kg | Oral |
| Subject | Tacrolimus | Small molecule | 0.05 mg/kg | — |
| Subject | Tacrolimus | Small molecule | 0.1 mg/kg | — |